Antitrust & Intellectual Property

Generic Drugs Pricing Antitrust

Issue: Alleged nationwide price-fixing conspiracies

Beginning in February 2015, Lieff Cabraser conducted an extensive investigation into dramatic price increases of certain generic drugs. Lieff Cabraser worked alongside economists and industry experts and interviewed industry participants to evaluate possible misconduct.

In December of 2016, Lieff Cabraser, with co-counsel, filed the first case alleging price-fixing of levothyroxine, the primary treatment for hypothyroidism, among the most widely prescribed drugs in the world. Lieff Cabraser also played a significant role in similar litigation over the drug propranolol in the Southern District of New York, and the drug clomipramine in the District of New Jersey. These cases, and other similar cases, were consolidated and transferred to the Eastern District of Pennsylvania as In Re: Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724.

On May 19, 2017, Elizabeth Cabraser and Lieff Cabraser were named to the End-Payer Plaintiffs’ Steering Committee.